CD274 and neoplasm: However, the therapeutic efficacy of immune checkpoint blockade (ICB) in OS remains inconsistent due to the heterogeneous and dynamic expression of PD-L1 within the tumor microenvironment (Panez-Toro et al., 2023; Tawbi et al., 2017; Boye et al., 2021; Le Cesne et al., 2019).